Using more selective dopaminergic receptor subtype agonists, the motivational deficits induced by the SNc lesions were specifically reversed by the D3R agonist PD-128907, but not by the D1R agonists SKF-38393 and SKF-82958, nor by the D2R agonist sumanirole.62 Taken together, these data confirm the implication of dopamine and point toward the targeting of D3R for reversing the motivational deficits related to PD. The gene discussed is DRD2; the disease is Parkinson disease.